Teratogenic study of doxycycline

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Objective: To study the human teratogenic risk of doxycycline treatment during pregnancy. Methods: Paired analysis of cases with congenital abnormalities and matched healthy controls was performed in the large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1992. Results: Of 32,804 pregnant women who had infants with no defects in the study period (control group), 63 (0.19%) were treated with doxycycline. Of 18,515 pregnant women who had offspring with congenital abnormalities, 56 (0.30%) were treated with doxycycline, a rate that is higher than that of the control group (P = .01). However, the case-control pair analysis did not show a significantly higher rate of doxycycline treatment in the second and third months of gestation in any group of congenital abnormalities. Conclusions: Treatment with doxycycline during pregnancy presents very little if any teratogenic risk to the fetus. Thus, if doxycycline treatment is necessary during pregnancy, there would appear to be no contraindication.

Original languageEnglish
Pages (from-to)524-528
Number of pages5
JournalObstetrics and Gynecology
Volume89
Issue number4
DOIs
Publication statusPublished - Apr 1997

Fingerprint

Doxycycline
Pregnancy
Pregnant Women
Control Groups
Therapeutics
Fetus
Population

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Teratogenic study of doxycycline. / Czeizel, E.; Rockenbauer, M.

In: Obstetrics and Gynecology, Vol. 89, No. 4, 04.1997, p. 524-528.

Research output: Contribution to journalArticle

@article{d2896a1a35f047bab84fac0643499442,
title = "Teratogenic study of doxycycline",
abstract = "Objective: To study the human teratogenic risk of doxycycline treatment during pregnancy. Methods: Paired analysis of cases with congenital abnormalities and matched healthy controls was performed in the large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1992. Results: Of 32,804 pregnant women who had infants with no defects in the study period (control group), 63 (0.19{\%}) were treated with doxycycline. Of 18,515 pregnant women who had offspring with congenital abnormalities, 56 (0.30{\%}) were treated with doxycycline, a rate that is higher than that of the control group (P = .01). However, the case-control pair analysis did not show a significantly higher rate of doxycycline treatment in the second and third months of gestation in any group of congenital abnormalities. Conclusions: Treatment with doxycycline during pregnancy presents very little if any teratogenic risk to the fetus. Thus, if doxycycline treatment is necessary during pregnancy, there would appear to be no contraindication.",
author = "E. Czeizel and M. Rockenbauer",
year = "1997",
month = "4",
doi = "10.1016/S0029-7844(97)00005-7",
language = "English",
volume = "89",
pages = "524--528",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Teratogenic study of doxycycline

AU - Czeizel, E.

AU - Rockenbauer, M.

PY - 1997/4

Y1 - 1997/4

N2 - Objective: To study the human teratogenic risk of doxycycline treatment during pregnancy. Methods: Paired analysis of cases with congenital abnormalities and matched healthy controls was performed in the large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1992. Results: Of 32,804 pregnant women who had infants with no defects in the study period (control group), 63 (0.19%) were treated with doxycycline. Of 18,515 pregnant women who had offspring with congenital abnormalities, 56 (0.30%) were treated with doxycycline, a rate that is higher than that of the control group (P = .01). However, the case-control pair analysis did not show a significantly higher rate of doxycycline treatment in the second and third months of gestation in any group of congenital abnormalities. Conclusions: Treatment with doxycycline during pregnancy presents very little if any teratogenic risk to the fetus. Thus, if doxycycline treatment is necessary during pregnancy, there would appear to be no contraindication.

AB - Objective: To study the human teratogenic risk of doxycycline treatment during pregnancy. Methods: Paired analysis of cases with congenital abnormalities and matched healthy controls was performed in the large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1992. Results: Of 32,804 pregnant women who had infants with no defects in the study period (control group), 63 (0.19%) were treated with doxycycline. Of 18,515 pregnant women who had offspring with congenital abnormalities, 56 (0.30%) were treated with doxycycline, a rate that is higher than that of the control group (P = .01). However, the case-control pair analysis did not show a significantly higher rate of doxycycline treatment in the second and third months of gestation in any group of congenital abnormalities. Conclusions: Treatment with doxycycline during pregnancy presents very little if any teratogenic risk to the fetus. Thus, if doxycycline treatment is necessary during pregnancy, there would appear to be no contraindication.

UR - http://www.scopus.com/inward/record.url?scp=0031127095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031127095&partnerID=8YFLogxK

U2 - 10.1016/S0029-7844(97)00005-7

DO - 10.1016/S0029-7844(97)00005-7

M3 - Article

C2 - 9083306

AN - SCOPUS:0031127095

VL - 89

SP - 524

EP - 528

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 4

ER -